More viscous than olive oil
When administering an antibody medication subcutaneously, no more than two millilitres can be injected per syringe.
This small quantity must contain a very high level of antibodies in order for the medication to be effective.
This makes the medication highly viscous.
“It is not uncommon for the viscosity to be higher than that of olive oil, which can make subcutaneous injection very difficult,” says Schäfer.
“This challenge has complicated the development and application of biopharmaceutical formulations for a long time.”
Found in the journal, The Journal of Physical Chemistry Letters.
Until now, improving these formulations has largely relied on trial and error – testing countless combinations of ingredients and conditions, which is both time-consuming and resource-intensive.
“We thus set out to use chemically realistic computer simulations to predict the consistency of various formulations,” says Dr. Tobias Prass from the Centre for Theoretical Chemistry, first author of the publication.
The researchers developed a coarse-grained simulation approach that is far more efficient yet still captures the key chemical interactions.
“Our approach is around a thousand times faster than atomistic simulations, while closely matching experimental results,” explains Prass.
Saving time and resources
“The simulations not only complement and explain our experimental findings”, adds Dr. Michaela Blech from Boehringer Ingelheim Pharma GmbH & Co.KG.
“They also enable the rational design of new experiments and can predict their outcome, saving time and resources by filtering out unpromising candidates and conditions early in development.”
Source: Ruhr-University Bochum
We are an independent charity and are not backed by a large company or society. We raise every penny ourselves to improve the standards of cancer care through education. You can help us continue our work to address inequalities in cancer care by making a donation.
Any donation, however small, contributes directly towards the costs of creating and sharing free oncology education.
Together we can get better outcomes for patients by tackling global inequalities in access to the results of cancer research.
Thank you for your support.